


## di-DTPA-LTL

Cat. No.:	HY-155446
Molecular Formula:	C <sub>52</sub> H <sub>82</sub> N <sub>12</sub> O <sub>23</sub>
Molecular Weight:	1243.27
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with <sup>111</sup>In (indium) and <sup>131</sup>I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled <sup>111</sup>In) into the patients<sup>[1][2][3]</sup>.

### REFERENCES

- [1]. Gruaz-Guyon A, et al. Recent advances in pretargeted radioimmunotherapy. *Curr Med Chem.* 2005;12(3):319-38.
- [2]. Gautherot E, et al. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten[J]. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 1997, 80(S12): 2618-2623.
- [3]. Aarts F, et al. Pretargeted radioimmunosctigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-diethylenetriaminepentaacetic acid F (ab') 2 antibody[J]. *Cancer*, 2010, 116(S4): 1111-1117.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA